Log In
BCIQ
Print this Print this
 

Botulism antitoxin heptavalent (BAT)

  Manage Alerts
Collapse Summary General Information
Company Emergent BioSolutions Inc.
DescriptionHeptavalent hyperimmune preparation containing neutralizing antibodies to the 7 different botulinum toxin types
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentApproved
Standard IndicationClostridium
Indication DetailsTreat botulism
Regulatory Designation U.S. - Priority Review (Treat botulism)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$222.0M

$222.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/21/2014

$222.0M

$222.0M

0

Get a free BioCentury trial today